A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.
Epistemonikos ID: da55d738a10105e6c6874cf46a7e7aeb60187d44
First added on: May 12, 2024